Table 3.
In vitro activity of miltefosine, benznidazole, and nifurtimox on trypomastigote and intracellular amastigote stages of Trypanosoma cruzi (VD strain) and their cytotoxic effects on Vero cells.
| Drug | LC50(Anti-trypomastigote activity) | IC50(Anti-amastigote activity) | CC50(Host-cell cytotoxic activity) | SI |
|---|---|---|---|---|
| MLT | 31.17 (29.56; 32.87) |
0.51 (0.48; 0,55) |
57.36 (36.14; 91.05) |
112 |
| BZ | 9.43 (8.62; 10.32) |
0.73 (0.69; 0.77) |
> 640 | > 876 |
| NFX | 2.35 (2.00; 2.78) |
0.15 (0.13; 0.17) |
> 220 | > 1.497 |
MLT, miltefosine. BZ, benznidazole. NFX, nifurtimox.
LC50: lytic concentration 50%; drug concentration needed to reduce the trypomastigote motility by 50% compared to the infected non-treated control.
IC50: inhibitory concentration 50%; drug concentration needed to reduce the intracellular amastigote development by 50% compared to the infected non-treated control.
CC50, cell toxicity 50%; drug concentration capable of reducing the cell viability by 50% compared to the non-treated cell culture.
SI, selectivity index. SI, CC50/IC50.
Values are expressed in µM and reported as the mean concentration and the 95% confidence interval (IC95%).